Oral sildenafil in skin ulcers secondary to systemic sclerosis

Digital ulcers (DUs) are a major clinical problem in scleroderma patients, associated with reduced quality of life, pain, and disability, and resulting in loss of productivity and mutilation that c...

[1]  P. Shenoy,et al.  Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. , 2010, Rheumatology.

[2]  G. Burmester,et al.  Concise Report , 2022 .

[3]  J. Gerss,et al.  Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors , 2009, The British journal of dermatology.

[4]  R. Landewé,et al.  EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR) , 2009, Annals of the rheumatic diseases.

[5]  C. Derk,et al.  Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication , 2009 .

[6]  C. Derk,et al.  Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication. , 2009, Expert opinion on investigational drugs.

[7]  M. Cerinic,et al.  Vascular complications of scleroderma. , 2007, Autoimmunity reviews.

[8]  A. Vaglio,et al.  Chronic periaortitis and HLA-DRB1*03: another clue to an autoimmune origin. , 2006, Arthritis and rheumatism.

[9]  M. Böhm,et al.  Sildenafil in the Treatment of Raynaud’s Phenomenon Resistant to Vasodilatory Therapy , 2005, Circulation.

[10]  M. Mayes,et al.  Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. , 2004, Arthritis and rheumatism.

[11]  R. Wise,et al.  Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. , 1992, The Journal of rheumatology.